Aperus Pharma

Aperus Pharma is a private Hungarian drug development company focused on small-molecule therapies for neurodegenerative disease, with a primary emphasis on Alzheimer's disease. The company's lead and apparently sole disclosed clinical asset is Q134R, a multi-target small molecule licensed from or originated by majority owner Avidin, which Aperus says has completed a Phase I/a first-in-human study in healthy volunteers. Aperus positions Q134R as a potential disease-modifying therapy with effects spanning NFAT-related signaling, neuronal cytoprotection, and modulation of GABAA-gated chloride channels. The company appears to operate as a project-focused vehicle that owns the patents and rights around Q134R and its related compound family, while being supported by shareholders including Avidin, DREM, and Hégely Holding. Publicly available information suggests a narrow pipeline centered on advancing Q134R for Alzheimer's disease rather than a broad multi-asset platform.